Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today its 2016 business outlook.
Healthcare analysts weighed in today on small-cap biotech companies Advaxis, Inc. (NASDAQ:ADXS) and Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), with positive ratings.
Considerable strength remains visible among biotechnology stocks, as reflected by the 2.25 percent gain being posted by the iShares NASDAQ Biotechnology Index today.
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to axalimogene …
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that it will present a poster on Advaxis’s Lm Technology™ cancer immunotherapy ADXS-HER2 …
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the European Medicines Agency (EMA) granted Orphan Drug Designation for ADXS-HER2 for …
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced the Company has received preliminary approval for a $1.
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, presented a poster featuring clinical development advances with its Lm Technology™ at the Society …
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the launch of a research collaboration with Memorial Sloan Kettering Cancer Center …
